Use of white blood cell growth factors and risk of acute myeloid leukemia or myelodysplastic syndrome among elderly patients with non-Hodgkin lymphoma

Cancer

Volumn 116, Issue 22, 2010, Pages 5279-5289

  Gruschkus, Stephen K ^a   Lairson, David ^a   Dunn, J Kay ^a   Risser, Jan ^a   Du, Xianglin L ^a  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

acute myeloid leukemia; chemotherapy; colony stimulating factor; myelodysplastic syndromes; non Hodgkin lymphoma

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC ANTIMETABOLITE; DNA TOPOISOMERASE INHIBITOR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; VINCA ALKALOID;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER RISK; COHORT ANALYSIS; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; DEATH; DISEASE ASSOCIATION; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; GERIATRIC PATIENT; HAZARD RATIO; HISTOLOGY; HUMAN; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MEDICARE; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; POPULATION RESEARCH; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COLONY-STIMULATING FACTORS; DRUG INTERACTIONS; FEMALE; HUMANS; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, NON-HODGKIN; MALE; MYELODYSPLASTIC SYNDROMES; RISK; SEER PROGRAM;

EID: 78449299171     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25525     Document Type: Article

References (36)

1. Vega-Stromberg T., Chemotherapy-induced secondary malignancies. J Infus Nurs. 2003; 26: 353-361.
2. Godley L, Larson R., The syndrome of therapy-related myelodysplasia and myeloid leukemia. In:, Bennett J, ed. The Myelodysplastic Syndromes: Pathology and Clinical Management. New York: Marcel Dekker, Inc; 2002: 139-176.
3. Leone G, Mele L, Pulsoni A, Equitani F, Pagano L., The incidence of secondary leukemias. Haematologica. 1999; 84: 937-945.
4. Travis LB, Curtis RE, Stovall M, et al. Risk of leukemia following treatment for non-Hodgkin's lymphoma. J Natl Cancer Inst. 1994; 86: 1450-1457.
5. Greene MH, Wilson J., Second cancer following lymphatic and hematopoietic cancers in Connecticut, 1935-82. Natl Cancer Inst Monogr. 1985; 68: 191-217.
6. Ingram L, Mott MG, Mann JR, et al. Second malignancies in children treated for non-Hodgkin's lymphoma and T-cell leukaemia with the UKCCSG regimens. Br J Cancer. 1987; 55: 463-466.
7. Lavey RS, Eby NL, Prosnitz LR., Impact on second malignancy risk of the combined use of radiation and chemotherapy for lymphomas. Cancer. 1990; 66: 80-88.
8. Pedersen-Bjergaard J, Ersboll J, Sorensen HM, et al. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. Ann Intern Med. 1985; 103: 195-200.
9. Pui CH., Therapy-related myeloid leukaemia. Lancet. 1990; 336: 1130-1131.
10. Armitage JO, Carbone PP, Connors JM, et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol. 2003; 21: 897-906.
11. Park D, Koeffler H., Therapy-related myelodysplastic syndromes. Semin Hematol. 1996; 33: 256-273.
12. Brodsky RA, Bedi A, Jones RJ., Are growth factors leukemogenic? Leukemia. 1996; 10: 175-177.
13. Relling MV, Boyett JM, Blanco JG, et al. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood. 2003; 101: 3862-3867.
14. Smith RE, Bryant J, DeCillis A, Anderson S,; National Surgical Adjuvant Breast and Bowel Project Experience. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol. 2003; 21: 1195-1204.
15. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003; 21: 1431-1439.
16. Papaldo P, Lopez M, Cortesi E, et al. Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide. J Clin Oncol. 2003; 21: 3462-3468.
17. Crump M, Tu D, Shepherd L, Levine M, Bramwell V, Pritchard K., Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003; 21: 3066-3071.
18. Venturini M, Del Mastro L, Aitini E, et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst. 2005; 97: 1724-1733.
19. Praga C, Bergh J, Bliss J, et al. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol. 2005; 23: 4179-4191.
20. Veyret C, Levy C, Chollet P, et al. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial. Cancer. 2006; 107: 2535-2544.
21. Hershman D, Neugut AI, Jacobson JS, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst. 2007; 99: 196-205.
22. Patt DA, Duan Z, Fang S, et al. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J Clin Oncol. 2007; 25: 3871-3876.
23. Le Deley MC, Suzan F, Cutuli B, et al. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol. 2007; 25: 292-300.
24. Repetto L, Balducci L., A case for geriatric oncology. Lancet Oncol. 2002; 3: 289-297.
25. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006; 24: 3187-3205.
26. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF., Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40 (8 suppl): IV-3-IV-18.
27. Clarke CA, Undurraga DM, Harasty PJ, et al. Changes in cancer registry coding for lymphoma subtypes: reliability over time and relevance for surveillance and study. Cancer Epidemiol Biomarkers Prev. 2006; 15: 630-638.
28. Klabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D., A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol. 2007; 17: 584-590.
29. Harrell F, Lee K., Verifying assumptions of the proportional hazards model. In: Proceedings of the 11th Annual SAS User's Group International 1986; 11: 823-828.
30. Lieschke GJ, Burgess AW., Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2). N Engl J Med. 1992; 327: 99-106.
31. Guillem V, Tormo M., Influence of DNA damage and repair upon the risk of treatment related leukemia. Leuk Lymphoma. 2008; 49: 204-217.
32. Kroft SH, Tallman MS, Shaw JM, et al. Myelodysplasia following treatment of chronic lymphocytic leukemia (CLL) with 2-chlorodeoxyadenosine (2-CdA) [abstract]. Leukemia. 1997; 11: 170.
33. Van Den Neste E, Louviaux I, Michaux JL, et al. Myelodysplastic syndrome with monosomy 5 and/or 7 following therapy with 2-chloro-2′- deoxyadenosine. Br J Haematol. 1999; 105: 268-270.
34. Robak T, Blonski JZ, Gora-Tybor J, et al. Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukemia treated with cladribine. Eur J Cancer. 2004; 40: 383-389.
35. Robak T., Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukemia. Hematology. 2004; 9: 387-400.
36. Cheson BD, Vena DA, Barrett J, Freidlin B., Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol. 1999; 17: 2454-2460.